Sino Biological (SHE: 301047), a leading biotech company in China, and BioGeometry have announced an expansion of their partnership to harness generative artificial intelligence (AI) for drug discovery. While the financial details of the deal remain undisclosed, the collaboration aims to combine Sino Bio’s advanced protein expression and wet-lab expertise with BioGeometry’s AI-driven protein design and optimization platform. This strategic alliance is designed to explore and capitalize on high-value market opportunities on a global scale.
BioGeometry utilizes diffusion models to forecast biomolecule structures through its GeoFlow protein foundation model, which was introduced and made freely accessible for non-commercial purposes earlier this year. Additionally, the company’s GeoForm tool, part of the GeoBiologics platform, is engineered to streamline protein design processes and minimize the number of required experiments. The partnership has already yielded successful developments in nanobodies and enzymes, with ambitions to further expand on these achievements. – Flcube.com
